{
    "medicine_id": "b60fd50c69cd4523af5a7d5a928a8e042d71711a",
    "platform_id": "DB06080",
    "metadata": {
        "name": "Caplyta 42 mg 1 Capsule",
        "composition": "42 mg 1 ABT 869",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in leukemia myeloid myelodysplastic syndrome and solid tumors",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "ABT 869 was effective in a broad range of cancers including small cell lung carcinoma colon carcinoma breast carcinoma and MV4 11 tumors in vitro and in vivo ABT 869 induced significant apoptosis in cells with FLT3 mutation in vitro IC50 value of 4 nM and profound anti leukemic effect in a mouse xenograft model However in vitro ABT 869 only shows minimal cytotoxic effect on AML cells with wild type FLT3 Based on the preclinical studies suggesting the role of VEGF pathways in leukemogenesis it is likely that the anti leukemic effect of ABT 869 will be best evaluated in vivo",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}